Provided by Tiger Fintech (Singapore) Pte. Ltd.

Castle Biosciences, Inc.

20.52
+0.45002.24%
Post-market: 20.520.00000.00%16:39 EDT
Volume:605.75K
Turnover:12.45M
Market Cap:585.11M
PE:33.10
High:21.01
Open:19.86
Low:19.76
Close:20.07
Loading ...

BTIG Keeps Their Buy Rating on Castle Biosciences (CSTL)

TIPRANKS
·
18 Mar

New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio

Business Wire
·
07 Mar

Castle Biosciences (CSTL) Gets a Buy from Scotiabank

TIPRANKS
·
03 Mar

What Is Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Doing?

Simply Wall St.
·
01 Mar

Castle Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
01 Mar

Q4 2024 Castle Biosciences Inc Earnings Call

Thomson Reuters StreetEvents
·
01 Mar

Castle Biosciences Is Maintained at Outperform by Baird

Dow Jones
·
28 Feb

Castle Biosciences price target raised to $37 from $36 at Baird

TIPRANKS
·
28 Feb

Castle Biosciences Inc (CSTL) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...

GuruFocus.com
·
28 Feb

Castle Biosciences, Inc. (CSTL) Surpasses Q4 Earnings and Revenue Estimates

Zacks
·
28 Feb

Castle Biosciences sees FY25 revenue $280M-$295M, consensus $269.06M

TIPRANKS
·
28 Feb

Castle Biosciences Q4 2024 GAAP EPS $0.32 Up From $(0.10) YoY, Sales $86.311M Beat $81.911M Estimate

Benzinga
·
28 Feb

BRIEF-Castle Biosciences Q4 Revenue USD 86.311 Million Vs. IBES Estimate USD 81.9 Million

Reuters
·
28 Feb

Castle Biosciences Inc - Expects 2025 Revenue Between $280-295 Million

THOMSON REUTERS
·
28 Feb

Castle Biosciences Inc FY2025 REV View $274.1 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
28 Feb

Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results

Business Wire
·
28 Feb